Ansbert Gadicke
Founder & Managing Partner, MPM BioImpact
Ansbert Gadicke is founder and managing partner of MPM BioImpact, the biotech venture firm he started in 1992. Trained as a physician, he did research at the German Cancer Research Center, at Harvard University and at the Whitehead Institute for Biomedical Research at MIT, and worked as a consultant at The Boston Consulting Group before founding MPM.
He has been a lead investor and board member at companies including BioMarin, Idenix Pharmaceuticals, Pharmasset, Mitobridge, TriNetX, Cullinan Therapeutics, ElevateBio, Orna Therapeutics and K2 Therapeutics. He serves on the Harvard Medical School Board of Fellows and the Research Advisory Council of Massachusetts General Hospital, and holds an MD from Goethe University Frankfurt.
On Open Door Salon, alongside Ying Huang of K2 Therapeutics, he described how large drug companies once doubted clinical data from China and explained why MPM licenses Chinese assets and does not take equity in Chinese companies. He said US founders should build truly new technologies, citing Orna Therapeutics, which Eli Lilly agreed to acquire.
Frequently Asked Questions About Ansbert Gadicke
Who is Ansbert Gadicke?
Ansbert Gadicke is founder and managing partner of MPM BioImpact, the biotech venture firm he started in 1992. Trained as a physician, he did research at the German Cancer Research Center, at Harvard University and at the Whitehead Institute for Biomedical Research at MIT before founding MPM.
Which companies has Ansbert Gadicke backed?
Ansbert Gadicke has been a lead investor and board member at companies including BioMarin, Idenix Pharmaceuticals, Pharmasset, Mitobridge, TriNetX, Cullinan Therapeutics, ElevateBio, Orna Therapeutics and K2 Therapeutics.
How does Ansbert Gadicke approach investing in Chinese drug assets?
Ansbert Gadicke said MPM BioImpact licenses drug candidates from China and, as a principle for now, does not take equity in Chinese companies, citing geopolitical risk, governance and the difficulty of exits. He said diligence on a China asset has to be as thorough as in the US, run by a local, bilingual team.
What does Ansbert Gadicke think US biotech founders should build?
Ansbert Gadicke said me-too products are no longer fundable in the US because similar candidates can be found in China, and that founders should work on truly new technologies and ideas, where the West still leads.
On Open Door Salon
“Ying Huang and Ansbert Gadicke on China Biotech Licensing, Deal Prices and Trust in Trial Data”
Ying Huang & Ansbert Gadicke · November 4, 2026
Episode page & show notes on Open Door Salon
In this episode
- Why no one believed Legend’s China data
- From Legend to K2: a Singapore hub-and-spoke model
- Why licensed Chinese assets lower development risk
- China’s biotech ecosystem, and whether India can match it
- Licensing over acquisition, and the end of the bargain era
- Founder expectations, and how US biotechs can compete
- New rules on Chinese assets in Washington and Beijing
- Diligence when a partner could become restricted
- Trial deaths, FDA audits and what has to go right
- What drew them to this work
- The hardest challenges of their careers
Topics
Watch on Open Door Salon
Open Door Salon brings life-sciences leaders into candid conversation. Every Monday, the week's takeaways land in your inbox.
Subscribe on Substack →